Screening and Prostate-Cancer Mortality in a Randomized European Study

Key Points

Key points are not available for this paper at this time.

Abstract

PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis. (Current Controlled Trials number, ISRCTN49127736.)

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Schröder et al. (Wed,) studied this question.

synapsesocial.com/papers/69dbd2bff7e0c66ced83666c https://doi.org/https://doi.org/10.1056/nejmoa0810084

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial2001 · 169 citations
2A Multiple Testing Procedure for Clinical Trials1979 · 3,346 citations
3Report of the consensus workshop on screening and global strategy for prostate cancer1995 · 62 citations
4The story of the European Randomized Study of Screening for Prostate Cancer2003 · 149 citations
5Interval Cancers in Prostate Cancer Screening: Comparing 2- and 4-Year Screening Intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam2007 · 71 citations